Lipid Nanocarrier-Based Drug Delivery Systems: Therapeutic Advances in the Treatment of Lung Cancer

References

• Schottenfeld D, Fraumeni JF. Cancer Epidemiology and Prevention. Oxford University Press; 2006.
   Google Scholar
• Sherman ME, Troester MA, Hoadley KA, Anderson WF. Morphological and molecular classification of human cancer. In: Cancer Epidemiology and Prevention. Oxford, UK: Oxford University Press; 2017.
   Google Scholar
• Blandin Knight S, Crosbie PA, Balata H, Chudziak J, Hussell T, Dive C. Progress and prospects of early detection in lung cancer. Open Biol. 2017;7(9):170070. doi:10.1098/rsob.170070
   PubMed Web of Science ®Google Scholar
• Pirker R. Conquering lung cancer: current status and prospects for the future. Pulmonology. 2020;26(5):283–290. doi:10.1016/j.pulmoe.2020.02.005
   PubMed Web of Science ®Google Scholar
• Norouzi M, Hardy P. Clinical applications of nanomedicines in lung cancer treatment. Acta biomaterialia. 2021;121:134–142. doi:10.1016/j.actbio.2020.12.009
   PubMed Web of Science ®Google Scholar
• Xu K, Zhang C, Du T, et al. Progress of exosomes in the diagnosis and treatment of lung cancer. Biomed Pharmacother. 2021;134:111111. doi:10.1016/j.biopha.2020.111111
   PubMed Web of Science ®Google Scholar
• Carrasco-Esteban E, Domínguez-Rullán JA, Barrionuevo-Castillo P, et al. Current role of nanoparticles in the treatment of lung cancer. J Clin Transl Res. 2021;7(2):140.
   PubMedGoogle Scholar
• Razak SA, Mohd Gazzali A, Fisol FA, et al. Advances in nanocarriers for effective delivery of docetaxel in the treatment of lung cancer: an overview. Cancers. 2021;13(3):400.
   PubMed Web of Science ®Google Scholar
• Dhiman N, Awasthi R, Sharma B, Kharkwal H, Kulkarni GT. Lipid nanoparticles as carriers for bioactive delivery. Front Chem. 2021;9:580118. doi:10.3389/fchem.2021.580118
   PubMed Web of Science ®Google Scholar
• Le TT, Andreadakis Z, Kumar A, et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020;19(5):305–306.
   PubMed Web of Science ®Google Scholar
• El-Hussein A, Manoto SL, Ombinda-Lemboumba S, Alrowaili ZA, Mthunzi-Kufa P. A review of chemotherapy and photodynamic therapy for lung cancer treatment. Anti-Cancer Agents Med Chem. 2021;21(2):149–161. doi:10.2174/1871520620666200403144945
   PubMed Web of Science ®Google Scholar
• Babu A, Templeton AK, Munshi A, Ramesh R. Nanoparticle-based drug delivery for therapy of lung cancer: progress and challenges. J Nanomater. 2013;2013:863951. doi:10.1155/2013/863951
   Web of Science ®Google Scholar
• Wu Q, Yang Z, Nie Y, Shi Y, Fan D. Multi-drug resistance in cancer chemotherapeutics: mechanisms and lab approaches. Cancer Lett. 2014;347(2):159–166. doi:10.1016/j.canlet.2014.03.013
   PubMed Web of Science ®Google Scholar
• Catalano A, Iacopetta D, Ceramella J, et al. Multidrug resistance (MDR): a widespread phenomenon in pharmacological therapies. Molecules. 2022;27(3):616. doi:10.3390/molecules27030616
   PubMed Web of Science ®Google Scholar
• Bukowski K, Kciuk M, Kontek R. Mechanisms of multidrug resistance in cancer chemotherapy. Int J Mol Sci. 2020;21(9):3233. doi:10.3390/ijms21093233
   PubMed Web of Science ®Google Scholar
• Yadav D, Kwak M, Chauhan PS, Puranik N, Lee PC, Jin J-O. Cancer Immunotherapy by Immune Checkpoint Blockade and Its Advanced Application Using Bio-Nanomaterials. Elsevier; 2022.
   Google Scholar
• Wang Y, Wang M, Wu HX, Xu RH. Advancing to the era of cancer immunotherapy. Cancer Commun. 2021;41(9):803–829. doi:10.1002/cac2.12178
   Web of Science ®Google Scholar
• Taefehshokr S, Parhizkar A, Hayati S, et al. Cancer immunotherapy: challenges and limitations. Pathol Res Pract. 2022;229:153723. doi:10.1016/j.prp.2021.153723
   PubMed Web of Science ®Google Scholar
• Hodroj K, Barthelemy D, Lega J-C, et al. Issues and limitations of available biomarkers for fluoropyrimidine-based chemotherapy toxicity, a narrative review of the literature. ESMO Open. 2021;6(3):100125. doi:10.1016/j.esmoop.2021.100125
   PubMed Web of Science ®Google Scholar
• Gavas S, Quazi S, Karpiński TM. Nanoparticles for cancer therapy: current progress and challenges. Nanoscale Res Lett. 2021;16(1):1–21.
   PubMed Web of Science ®Google Scholar
• Staff NP, Fehrenbacher JC, Caillaud M, Damaj MI, Segal RA, Rieger S. Pathogenesis of paclitaxel-induced peripheral neuropathy: a current review of in vitro and in vivo findings using rodent and human model systems. Exp Neurol. 2020;324:113121.
   PubMed Web of Science ®Google Scholar
• Feng B, Niu Z, Hou B, Zhou L, Li Y, Yu H. Enhancing triple negative breast cancer immunotherapy by ICG‐templated self‐assembly of paclitaxel nanoparticles. Adv Funct Mater. 2020;30(6):1906605.
   Web of Science ®Google Scholar
• Chowdhury P, Nagesh PK, Hatami E, et al. Tannic acid-inspired paclitaxel nanoparticles for enhanced anticancer effects in breast cancer cells. J Coll Interface Sci. 2019;535:133–148. doi:10.1016/j.jcis.2018.09.072
   PubMed Web of Science ®Google Scholar
• Massey AE, Sikander M, Chauhan N, et al. Next-generation paclitaxel-nanoparticle formulation for pancreatic cancer treatment. Nanomedicine. 2019;20:102027. doi:10.1016/j.nano.2019.102027
   PubMed Web of Science ®Google Scholar
• Cojocaru F-D, Botezat D, Gardikiotis I, et al. Nanomaterials designed for antiviral drug delivery transport across biological barriers. Pharmaceutics. 2020;12(2):171. doi:10.3390/pharmaceutics12020171
   PubMed Web of Science ®Google Scholar
• Yadav HK, Almokdad AA, Sumia I, Debe MS. Polymer-based nanomaterials for drug-delivery carriers. In: Nanocarriers for Drug Delivery. Elsevier; 2019:531–556.
   Google Scholar
• Cheng Z, Li M, Dey R, Chen Y. Nanomaterials for cancer therapy: current progress and perspectives. J Hematol Oncol. 2021;14(1):1–27.
   PubMed Web of Science ®Google Scholar
• Malam Y, Loizidou M, Seifalian AM. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci. 2009;30(11):592–599. doi:10.1016/j.tips.2009.08.004
   PubMed Web of Science ®Google Scholar
• Abarca-Cabrera L, Fraga-García P, Berensmeier S. Bio-nano interactions: binding proteins, polysaccharides, lipids and nucleic acids onto magnetic nanoparticles. Biomater Res. 2021;25(1):12. doi:10.1186/s40824-021-00212-y
   PubMedGoogle Scholar
• Duan Y, Dhar A, Patel C, et al. A brief review on solid lipid nanoparticles: part and parcel of contemporary drug delivery systems. RSC Adv. 2020;10(45):26777–26791. doi:10.1039/d0ra03491f
   PubMed Web of Science ®Google Scholar
• Reddy MSB, Ponnamma D, Choudhary R, Sadasivuni KK. A comparative review of natural and synthetic biopolymer composite scaffolds. Polymers. 2021;13(7):1105. doi:10.3390/polym13071105
   PubMed Web of Science ®Google Scholar
• Din FU, Aman W, Ullah I, et al. Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors. Int J Nanomedicine. 2017;12:7291–7309. doi:10.2147/IJN.S146315
   PubMed Web of Science ®Google Scholar
• Alavi M, Karimi N, Safaei M. Application of various types of liposomes in drug delivery systems. Adv Pharma Bull. 2017;7(1):3–9. doi:10.15171/apb.2017.002
   PubMed Web of Science ®Google Scholar
• Attama AA, Momoh MA, Builders PF. Lipid nanoparticulate drug delivery systems: a revolution in dosage form design and development. Recent Adv Novel Drug Carrier Syst. 2012;5:107–140.
   Google Scholar
• Bulbake U, Doppalapudi S, Kommineni N, Khan W. Liposomal Formulations in Clinical Use: an Updated Review. Pharmaceutics. 2017;9(2):12. doi:10.3390/pharmaceutics9020012
   PubMed Web of Science ®Google Scholar
• Shrestha H, Bala R, Arora S. Lipid-Based Drug Delivery Systems. J Pharma. 2014;2014:801820. doi:10.1155/2014/801820
   Google Scholar
• Yadav D, Sandeep K, Pandey D, Dutta RK. Liposomes for drug delivery. J Biotechnol Biomater. 2017;7(4):276. doi:10.4172/2155-952X.1000276
   Google Scholar
• Rommasi F, Esfandiari N. Liposomal nanomedicine: applications for drug delivery in cancer therapy. Nanoscale Res Lett. 2021;16(1):95. doi:10.1186/s11671-021-03553-8
   PubMed Web of Science ®Google Scholar
• Wakaskar RR. General overview of lipid-polymer hybrid nanoparticles, dendrimers, micelles, liposomes, spongosomes and cubosomes. J Drug Target. 2018;26(4):311–318. doi:10.1080/1061186X.2017.1367006
   PubMed Web of Science ®Google Scholar
• Ghasemiyeh P, Mohammadi-Samani S. Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: applications, advantages and disadvantages. Res Pharm Sci. 2018;13(4):288–303. doi:10.4103/1735-5362.235156
   PubMed Web of Science ®Google Scholar
• Yoon G, Park JW, Yoon I-S. Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs): recent advances in drug delivery. J Pharma Investig. 2013;43(5):353–362. doi:10.1007/s40005-013-0087-y
   Google Scholar
• Shiraishi K, Yokoyama M. Toxicity and immunogenicity concerns related to PEGylated-micelle carrier systems: a review. Sci Technol Adv Mater. 2019;20(1):324–336. doi:10.1080/14686996.2019.1590126
   PubMed Web of Science ®Google Scholar
• Chen B-M, Cheng T-L, Roffler SR. Polyethylene glycol immunogenicity: theoretical, clinical, and practical aspects of anti-polyethylene glycol antibodies. ACS Nano. 2021;15(9):14022–14048. doi:10.1021/acsnano.1c05922
   PubMed Web of Science ®Google Scholar
• Chang H-I, Yeh M-K. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int J Nanomedicine. 2012;7:49–60. doi:10.2147/IJN.S26766
   PubMed Web of Science ®Google Scholar
• Nakhaei P, Margiana R, Bokov DO, et al. Liposomes: structure, biomedical applications, and stability parameters with emphasis on cholesterol. Front Bioengine Biotechnol. 2021;9. doi:10.3389/fbioe.2021.705886
   PubMed Web of Science ®Google Scholar
• Pinot M, Vanni S, Pagnotta S, et al. Polyunsaturated phospholipids facilitate membrane deformation and fission by endocytic proteins. Science. 2014;345(6197):693–697. doi:10.1126/science.1255288
   PubMed Web of Science ®Google Scholar
• van Hoogevest P, Wendel A. The use of natural and synthetic phospholipids as pharmaceutical excipients. Eur J Lipid Sci Technol. 2014;116(9):1088–1107. doi:10.1002/ejlt.201400219
   PubMed Web of Science ®Google Scholar
• Yingchoncharoen P, Kalinowski DS, Richardson DR. Lipid-based drug delivery systems in cancer therapy: what is available and what is yet to come. Pharmacol Rev. 2016;68(3):701–787. doi:10.1124/pr.115.012070
   PubMed Web of Science ®Google Scholar
• Zhu X, Kong Y, Liu Q, et al. Inhalable dry powder prepared from folic acid-conjugated docetaxel liposomes alters pharmacodynamic and pharmacokinetic properties relevant to lung cancer chemotherapy. Pulm Pharmacol Ther. 2019;55:50–61. doi:10.1016/j.pupt.2019.02.001
   PubMed Web of Science ®Google Scholar
• Gandhi M, Pandya T, Gandhi R, et al. Inhalable liposomal dry powder of gemcitabine-HCl: formulation, in vitro characterization and in vivo studies. Int J Pharm. 2015;496(2):886–895. doi:10.1016/j.ijpharm.2015.10.020
   PubMed Web of Science ®Google Scholar
• Lin C, Wong BCK, Chen H, et al. Pulmonary delivery of triptolide-loaded liposomes decorated with anti-carbonic anhydrase IX antibody for lung cancer therapy. Sci Rep. 2017;7(1):1–12. doi:10.1038/s41598-016-0028-x
   PubMedGoogle Scholar
• Jiang K, Shen M, Xu W. Arginine, glycine, aspartic acid peptide-modified paclitaxel and curcumin co-loaded liposome for the treatment of lung cancer: in vitro/vivo evaluation. Int J Nanomedicine. 2018;13:2561. doi:10.2147/IJN.S157746
   PubMed Web of Science ®Google Scholar
• Jiménez-López J, Bravo-Caparrós I, Cabeza L, et al. Paclitaxel antitumor effect improvement in lung cancer and prevention of the painful neuropathy using large pegylated cationic liposomes. Biomed Pharmacother. 2021;133:111059. doi:10.1016/j.biopha.2020.111059
   PubMed Web of Science ®Google Scholar
• Riaz MK, Zhang X, Wong KH, et al. Pulmonary delivery of transferrin receptors targeting peptide surface-functionalized liposomes augments the chemotherapeutic effect of quercetin in lung cancer therapy. Int J Nanomedicine. 2019;14:2879. doi:10.2147/IJN.S192219
   PubMed Web of Science ®Google Scholar
• Ghosh B, Biswas S. Polymeric micelles in cancer therapy: state of the art. J Control Release. 2021;332:127–147. doi:10.1016/j.jconrel.2021.02.016
   PubMed Web of Science ®Google Scholar
• Tumbrink HL, Heimsoeth A, Sos ML. The next tier of EGFR resistance mutations in lung cancer. Oncogene. 2021;40(1):1–11. doi:10.1038/s41388-020-01510-w
   PubMed Web of Science ®Google Scholar
• Leng D, Hu J, Huang X, et al. Promoted delivery of salinomycin to lung cancer through epidermal growth factor receptor aptamers coupled DSPE-PEG2000 nanomicelles. J Nanosci Nanotechnol. 2018;18(8):5242–5251. doi:10.1166/jnn.2018.15424
   PubMed Web of Science ®Google Scholar
• Shen Y, Li X, Dong D, Zhang B, Xue Y, Shang P. Transferrin receptor 1 in cancer: a new sight for cancer therapy. Am J Cancer Res. 2018;8(6):916.
   PubMed Web of Science ®Google Scholar
• Wang J, Su G, Yin X, et al. Non-small cell lung cancer-targeted, redox-sensitive lipid-polymer hybrid nanoparticles for the delivery of a second-generation irreversible epidermal growth factor inhibitor—Afatinib: in vitro and in vivo evaluation. Biomed Pharmacother. 2019;120:109493. doi:10.1016/j.biopha.2019.109493
   PubMed Web of Science ®Google Scholar
• Chan M-H, Chan Y-C, Liu R-S, Hsiao MJN. A selective drug delivery system based on phospholipid-type nanobubbles for lung cancer therapy. Nanomedicine. 2020;15(27):2689–2705. doi:10.2217/nnm-2020-0273
   PubMed Web of Science ®Google Scholar
• Paliwal R, Paliwal SR, Kenwat R, Kurmi BD, Sahu MK. Solid lipid nanoparticles: a review on recent perspectives and patents. Expert Opin Therap Patents. 2020;30(3):179–194. doi:10.1080/13543776.2020.1720649
   PubMed Web of Science ®Google Scholar
• da Rocha MCO, da Silva PB, Radicchi MA, et al. Docetaxel-loaded solid lipid nanoparticles prevent tumor growth and lung metastasis of 4T1 murine mammary carcinoma cells. J Nanobiotechnol. 2020;18(1):1–20.
   PubMed Web of Science ®Google Scholar
• Han Y, Zhang P, Chen Y, Sun J, Kong F. Co-delivery of plasmid DNA and doxorubicin by solid lipid nanoparticles for lung cancer therapy. Int J Mol Med. 2014;34(1):191–196. doi:10.3892/ijmm.2014.1770
   PubMed Web of Science ®Google Scholar
• Pi C, Zhao W, Zeng M, et al. Anti-lung cancer effect of paclitaxel solid lipid nanoparticles delivery system with curcumin as co-loading partner in vitro and in vivo. Drug Delivery. 2022;29(1):1878–1891. doi:10.1080/10717544.2022.2086938
   PubMed Web of Science ®Google Scholar
• Yi Y, Liang A-H, Liu T, Zhao Y, Cao C-Y. Analysis of causes for adverse reaction of Yuxingcao injection. Zhongguo Zhong Yao Za Zhi. 2008;33(21):2439–2442.
   PubMedGoogle Scholar
• Zhao Y, Chang Y-X, Hu X, Liu C-Y, Quan L-H, Liao Y. Solid lipid nanoparticles for sustained pulmonary delivery of Yuxingcao essential oil: preparation, characterization and in vivo evaluation. Int J Pharma. 2017;516(1–2):364–371. doi:10.1016/j.ijpharm.2016.11.046
   PubMed Web of Science ®Google Scholar
• Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev. 2021;6(12):1078–1094. doi:10.1038/s41578-021-00358-0
   Google Scholar
• Schoenmaker L, Witzigmann D, Kulkarni JA, et al. mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability. Int J Pharma. 2021;601:120586. doi:10.1016/j.ijpharm.2021.120586
   PubMed Web of Science ®Google Scholar
• Kowalski PS, Rudra A, Miao L, Anderson DG. Delivering the messenger: advances in technologies for therapeutic mRNA delivery. Mol Ther. 2019;27(4):710–728. doi:10.1016/j.ymthe.2019.02.012
   PubMed Web of Science ®Google Scholar
• Chen J, Ye Z, Huang C, et al. Lipid nanoparticle-mediated lymph node–targeting delivery of mRNA cancer vaccine elicits robust CD8+ T cell response. Proc Natl Acad Sci USA. 2022;119(34):e2207841119. doi:10.1073/pnas.2207841119
   PubMed Web of Science ®Google Scholar
• Hwang J, An E-K, Kim S-J, Zhang W, Jin J. Escherichia coli mimetic gold nanorod-mediated photo-and immunotherapy for treating cancer and its metastasis. ACS Nano. 2022;16(5):8472–8483. doi:10.1021/acsnano.2c03379
   PubMed Web of Science ®Google Scholar
• Zhang W, Xu L, Park H-B, et al. Escherichia coli adhesion portion FimH functions as an adjuvant for cancer immunotherapy. Protein Cell. 2020;11(1):1–14. doi:10.1007/s13238-019-0623-2
   PubMedGoogle Scholar
• Yan J, Zhang Y, Du S, et al. Nanomaterials mediated co‐stimulation of toll‐like receptors and CD40 for antitumor immunity. Adv Mater. 2022;34:2207486. doi:10.1002/adma.202207486
   Web of Science ®Google Scholar
• Nakamura T, Sato T, Endo R, et al. STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation. J Immunother Cancer. 2021;9(7):154.
   Web of Science ®Google Scholar
• Jaiswal P, Gidwani B, Vyas A. Nanostructured lipid carriers and their current application in targeted drug delivery. Artif Cells Nanomed Biotechnol. 2016;44(1):27–40. doi:10.3109/21691401.2014.909822
   PubMed Web of Science ®Google Scholar
• Haider M, Abdin SM, Kamal L, Orive G. Nanostructured lipid carriers for delivery of chemotherapeutics: a review. Pharmaceutics. 2020;12(3):288. doi:10.3390/pharmaceutics12030288
   PubMed Web of Science ®Google Scholar
• Elmowafy M, Al-Sanea MM. Nanostructured lipid carriers (NLCs) as drug delivery platform: advances in formulation and delivery strategies. Saudi Pharm J. 2021;29(9):999–1012. doi:10.1016/j.jsps.2021.07.015
   PubMed Web of Science ®Google Scholar
• Fang C-L, Al-Suwayeh S, Fang J-Y. Nanostructured lipid carriers (NLCs) for drug delivery and targeting. Recent Pat Nanotechnol. 2013;7(1):41–55. doi:10.2174/187221013804484827
   PubMed Web of Science ®Google Scholar
• Chauhan I, Yasir M, Verma M, Singh AP. Nanostructured lipid carriers: a groundbreaking approach for transdermal drug delivery. Adv Pharma Bull. 2020;10(2):150. doi:10.34172/apb.2020.021
   PubMed Web of Science ®Google Scholar
• Poonia N, Kharb R, Lather V, Pandita D. Nanostructured lipid carriers: versatile oral delivery vehicle. Future Sci OA. 2016;2(3):FSO135. doi:10.4155/fsoa-2016-0030
   PubMed Web of Science ®Google Scholar
• Salvi VR, Pawar P. Nanostructured lipid carriers (NLC) system: a novel drug targeting carrier. J Drug Deliv Sci Technol. 2019;51:255–267. doi:10.1016/j.jddst.2019.02.017
   Web of Science ®Google Scholar
• Izza NM, Suga K, Okamoto Y, et al. Systematic characterization of nanostructured lipid carriers from cetyl palmitate/caprylic triglyceride/tween 80 mixtures in an aqueous environment. Langmuir. 2021;37(14):4284–4293. doi:10.1021/acs.langmuir.1c00270
   PubMed Web of Science ®Google Scholar
• Han Y, Li Y, Zhang P, et al. Nanostructured lipid carriers as novel drug delivery system for lung cancer gene therapy. Pharm Dev Technol. 2016;21(3):277–281. doi:10.3109/10837450.2014.996900
   PubMed Web of Science ®Google Scholar
• Cao C, Wang Q, Liu Y. Lung cancer combination therapy: doxorubicin and β-elemene co-loaded, pH-sensitive nanostructured lipid carriers. In: Drug Design, Development and Therapy. Taylor & Francis; 2019:1087–1098.
   Google Scholar
• Guo S, Zhang Y, Wu Z, et al. Synergistic combination therapy of lung cancer: cetuximab functionalized nanostructured lipid carriers for the co-delivery of paclitaxel and 5-demethylnobiletin. Biomed Pharmacother. 2019;118:109225. doi:10.1016/j.biopha.2019.109225
   PubMed Web of Science ®Google Scholar
• Du M, Yin J. Dual-drug nanosystem: etoposide prodrug and cisplatin coloaded nanostructured lipid carriers for lung cancer therapy. In: Drug Design, Development and Therapy. Taylor & Francis; 2022:4139–4149.
   Google Scholar
• Qi L, Luo Q, Zhang Y, Jia F, Zhao Y, Wang F. Advances in toxicological research of the anticancer drug cisplatin. Chem Res Toxicol. 2019;32(8):1469–1486. doi:10.1021/acs.chemrestox.9b00204
   PubMed Web of Science ®Google Scholar
• Patel K, Bothiraja C, Mali A, Kamble R. Investigation of sorafenib tosylate loaded liposomal dry powder inhaler for the treatment of non-small cell lung cancer. Particulate Sci Technol. 2021;39(8):990–999. doi:10.1080/02726351.2021.1906367
   Web of Science ®Google Scholar
• Berkenfeld K, Lamprecht A, McConville JT. Devices for dry powder drug delivery to the lung. AAPS PharmSciTech. 2015;16(3):479–490. doi:10.1208/s12249-015-0317-x
   PubMed Web of Science ®Google Scholar
• Zhang T, Chen Y, Ge Y, Hu Y, Li M, Jin Y. Inhalation treatment of primary lung cancer using liposomal curcumin dry powder inhalers. Acta Pharm Sin B. 2018;8(3):440–448. doi:10.1016/j.apsb.2018.03.004
   PubMed Web of Science ®Google Scholar
• Adel IM, ElMeligy MF, Abdelrahim MEA, et al. Design and characterization of spray-dried proliposomes for the pulmonary delivery of curcumin. Int J Nanomedicine. 2021;16:2667–2687. doi:10.2147/IJN.S306831
   PubMed Web of Science ®Google Scholar
• Parvathaneni V, Kulkarni NS, Shukla SK, et al. Systematic development and optimization of inhalable pirfenidone liposomes for non-small cell lung cancer treatment. Pharmaceutics. 2020;12(3):206. doi:10.3390/pharmaceutics12030206
   PubMed Web of Science ®Google Scholar
• Chen T, Gong T, Zhao T, Fu Y, Zhang Z, Gong T. A comparison study between lycobetaine-loaded nanoemulsion and liposome using nRGD as therapeutic adjuvant for lung cancer therapy. Eur J Pharm Sci. 2018;111:293–302. doi:10.1016/j.ejps.2017.09.041
   PubMed Web of Science ®Google Scholar
• Naik H, Sonju JJ, Singh S, et al. Lipidated peptidomimetic ligand-functionalized HER2 targeted liposome as nano-carrier designed for doxorubicin delivery in cancer therapy. Pharmaceuticals. 2021;14(3):221. doi:10.3390/ph14030221
   Web of Science ®Google Scholar
• Miao YQ, Chen MS, Zhou X, et al. Chitosan oligosaccharide modified liposomes enhance lung cancer delivery of paclitaxel. Acta Pharmacol Sin. 2021;42(10):1714–1722. doi:10.1038/s41401-020-00594-0
   PubMed Web of Science ®Google Scholar
• Fu S, Zhao Y, Sun J, et al. Integrin α(v)β(3)-targeted liposomal drug delivery system for enhanced lung cancer therapy. Colloids Surf B Biointerfaces. 2021;201:111623. doi:10.1016/j.colsurfb.2021.111623
   PubMed Web of Science ®Google Scholar
• Ying X. Dequalinium-mediated mitochondria-targeting drug liposomes for the treatment of drug-resistant lung cancer. In: Liposome-Based Drug Delivery Systems. Springer; 2021:345–364.
   Google Scholar
• Onodera R, Morioka S, Unida S, Motoyama K, Tahara K, Takeuchi H. Design and evaluation of folate-modified liposomes for pulmonary administration in lung cancer therapy. Eur J Pharma Sci. 2022;168:106081. doi:10.1016/j.ejps.2021.106081
   PubMed Web of Science ®Google Scholar
• Khan A, Alsahli MA, Aljasir MA, et al. Experimental and theoretical insights on chemopreventive effect of the liposomal thymoquinone against benzo [a] pyrene-induced lung cancer in Swiss albino mice. J Inflamm Res. 2022;15:2263. doi:10.2147/JIR.S358632
   PubMed Web of Science ®Google Scholar
• Almurshedi AS, Radwan M, Omar S, et al. A novel pH-sensitive liposome to trigger delivery of Afatinib to cancer cells: impact on lung cancer therapy. J Mol Liq. 2018;259:154–166. doi:10.1016/j.molliq.2018.03.024
   Web of Science ®Google Scholar
• Jin X, Yang Q, Cai N, Zhang Z. A cocktail of betulinic acid, parthenolide, honokiol and ginsenoside Rh2 in liposome systems for lung cancer treatment. Nanomedicine. 2020;15(1):41–54. doi:10.2217/nnm-2018-0479
   PubMed Web of Science ®Google Scholar
• Wang Y, Fu M, Liu J, et al. Inhibition of tumor metastasis by targeted daunorubicin and dioscin codelivery liposomes modified with PFV for the treatment of non-small-cell lung cancer. Int J Nanomedicine. 2019;14:4071. doi:10.2147/IJN.S194304
   PubMed Web of Science ®Google Scholar
• Ma J, Zhuang H, Zhuang Z, et al. Development of docetaxel liposome surface modified with CD133 aptamers for lung cancer targeting. Artif Cells, Nanomed Biotechnol. 2018;46(8):1864–1871. doi:10.1080/21691401.2017.1394874
   PubMed Web of Science ®Google Scholar
• Gai C, Liu C, Wu X, et al. MT1DP loaded by folate-modified liposomes sensitizes erastin-induced ferroptosis via regulating miR-365a-3p/NRF2 axis in non-small cell lung cancer cells. Cell Death Dis. 2020;11(9):1–11. doi:10.1038/s41419-020-02939-3
   PubMed Web of Science ®Google Scholar
• Tie Y, Zheng H, He Z, et al. Targeting folate receptor β positive tumor-associated macrophages in lung cancer with a folate-modified liposomal complex. Signal Transduct Target Ther. 2020;5(1):1–15. doi:10.1038/s41392-020-0115-0
   PubMed Web of Science ®Google Scholar
• Zhang C, Zhang S, Zhi D, Zhao Y, Cui S, Cui J. Co-delivery of paclitaxel and survivin siRNA with cationic liposome for lung cancer therapy. Colloids Surf A. 2020;585:124054. doi:10.1016/j.colsurfa.2019.124054
   Google Scholar
• Zhang M, Li M, Du L, Zeng J, Yao T, Jin Y. Paclitaxel-in-liposome-in-bacteria for inhalation treatment of primary lung cancer. Int J Pharm. 2020;578:119177. doi:10.1016/j.ijpharm.2020.119177
   PubMed Web of Science ®Google Scholar
• Moosavian SA, Bianconi V, Pirro M, Sahebkar A. Challenges and pitfalls in the development of liposomal delivery systems for cancer therapy. Semin Cancer Biol. 2021;69:337–348. doi:10.1016/j.semcancer.2019.09.025
   PubMed Web of Science ®Google Scholar
• Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S. Advances and challenges of liposome assisted drug delivery. Front Pharmacol. 2015;6:286. doi:10.3389/fphar.2015.00286
   PubMed Web of Science ®Google Scholar
• Lei Y, Li X, Huang Q, Zheng X, Liu M. Progress and challenges of predictive biomarkers for immune checkpoint blockade. Front Oncol. 2021;11. doi:10.3389/fonc.2021.617335
   Web of Science ®Google Scholar
• Yao Y, Zhou Y, Liu L, et al. Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance. Front Mol Biosci. 2020;7. doi:10.3389/fmolb.2020.00193
   Web of Science ®Google Scholar
• Subhan MA, Choudhury KP, Neogi N. Advances with molecular nanomaterials in industrial manufacturing applications. Nanomanufacturing. 2021;1(2):75–97. doi:10.3390/nanomanufacturing1020008
   Google Scholar
• Pandey H, Rani R, Agarwal V. Liposome and their applications in cancer therapy. Braz Archiv Biol Technol. 2016;59. doi:10.1590/1678-4324-2016150477
   Web of Science ®Google Scholar
• Gagliardi A, Giuliano E, Venkateswararao E, et al. Biodegradable polymeric nanoparticles for drug delivery to solid tumors. Front Pharmacol. 2021;12. doi:10.3389/fphar.2021.601626
   Web of Science ®Google Scholar